Enoxaparin Sodium

CHEMBL1201476 Phase 4 承認済み Oligosaccharide
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

This injectable blood thinner works by blocking certain clotting proteins to prevent dangerous blood clots from forming or getting larger. It is commonly used to prevent clots after surgery and to treat deep vein thrombosis and pulmonary embolism.

治療領域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This injectable blood thinner works by blocking certain clotting proteins to prevent dangerous blood clots from forming or getting larger. It is commonly used to prevent clots after surgery and to treat deep vein thrombosis and pulmonary embolism.

Yes, Enoxaparin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201476. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.